Watch our latest webinar to learn how the TissueCypher® Barrett’s Esophagus Assay may be an important new precision medicine tool for today’s Barrett’s esophagus expert.


View Webinar


Don't Miss the News from Major GI Conferences in 2019


At DDW in May, Mike Hoerres, CEO, Cernostics was featured in a Roving Reporter Interview from the EndoscopyNow App.

See the full video interview by downloading the app on your mobile device.


App Store




Barrett's Esophagus & Esophageal Cancer

Three million people in the U.S. have Barrett's Esophagus, a known precursor to esophageal cancer. Until now, identifying which patients are at greatest risk for esophageal cancer has been impossible. Cernostics is looking to change that… Learn how
View All News
Cernostics Announces Blinded, Independent Validation of TissueCypher ® Performance for Predicting Risk of Progression to Esophageal Cancer in Patients with Non-Dysplastic BE... Read More
Cernostics Announces Groundbreaking Data Demonstrating TissueCypher® Performance for Predicting Risk of Progression to EAC in Patients with Non-Dysplastic BE... Read More
TissueCypher® Further Validated to Accurately Risk Stratify Barrett’s Esophagus Patients with Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences... Read More
01/09/2017 San Francisco, CA
JP Morgan Healthcare Conference
05/06/2017 Chicago, IL
Digestive Disease Week
10/13/2017 Orlando, FL
American College of Gastroenterology
Customer Service

Mon-Fri 9am-5pm (EST)